Format

Send to

Choose Destination
Curr Opin Investig Drugs. 2008 Nov;9(11):1228-37.

Talarozole, a selective inhibitor of P450-mediated all-trans retinoic acid for the treatment of psoriasis and acne.

Author information

1
University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, NJ 07101, USA. geriaan@umdnj.edu

Abstract

Talarozole, being developed by Barrier Therapeutics Inc under license from Johnson & Johnson, is a potent and selective inhibitor of cytochrome P450 26-mediated breakdown of endogenous all-trans retinoic acid for the treatment of psoriasis and acne. Phase II clinical trials of an oral formulation of talarozole in patients with psoriasis and with acne, and a phase I clinical trial of a topical formulation have been completed. At the time of publication, Barrier Therapeutics had suspended the development of talarozole as part of a series of cost-cutting initiatives; the company had also been acquired by Stiefel Laboratories Inc. No formal announcement had been made regarding the further development of talarozole.

PMID:
18951302
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center